MIRA Key Statistics, Chart & Performance
The current stock price of MIRA is 1.49 USD. In the past month the price increased by 3.47%. In the past year, price increased by 18.25%.
MIRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.13 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.98 | 499.57B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.87 | 143.17B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.15 | 108.83B | ||
| ZTS | ZOETIS INC | 19.86 | 55.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 22.43B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.46 | 11.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.01B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.43B |
Related stock screener links
About MIRA
Company Profile
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Company Info
MIRA PHARMACEUTICALS INC
1200 Brickell Avenue, Suite 1950 #1183
Miami FLORIDA US
Employees: 3
Phone: 18133695150
MIRA PHARMACEUTICALS INC / MIRA FAQ
What does MIRA PHARMACEUTICALS INC do?
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
What is the stock price of MIRA PHARMACEUTICALS INC today?
The current stock price of MIRA is 1.49 USD. The price decreased by -1.32% in the last trading session.
Does MIRA stock pay dividends?
MIRA does not pay a dividend.
What is the ChartMill rating of MIRA PHARMACEUTICALS INC stock?
MIRA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in MIRA PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MIRA.
Can you provide the market cap for MIRA PHARMACEUTICALS INC?
MIRA PHARMACEUTICALS INC (MIRA) has a market capitalization of 62.40M USD. This makes MIRA a Micro Cap stock.
What is the outstanding short interest for MIRA PHARMACEUTICALS INC?
The outstanding short interest for MIRA PHARMACEUTICALS INC (MIRA) is 0.54% of its float.
MIRA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MIRA. When comparing the yearly performance of all stocks, MIRA is one of the better performing stocks in the market, outperforming 79.46% of all stocks.
MIRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MIRA. While MIRA has a great health rating, there are worries on its profitability.
MIRA Financial Highlights
Over the last trailing twelve months MIRA reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS decreased by -108.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -372.26% | ||
| ROE | -376.4% | ||
| Debt/Equity | 0 |
MIRA Forecast & Estimates
7 analysts have analysed MIRA and the average price target is 3.06 USD. This implies a price increase of 105.37% is expected in the next year compared to the current price of 1.49.